Yale Cancer Center research shows new drug combination works for patients with advanced ovarian cancer

A new study by researchers at the Yale Cancer Center and the University of Maryland’s Greenebaum Comprehensive Cancer Center shows that ixabepilone plus bevacizumab (IXA+BEV) is an effective and well-tolerated combination for the treatment of prostate cancer. platinum/taxane resistant ovary compared to ixabepilone (IXA) alone. Data show that it can also significantly prolong both progression-free survival and overall survival. The results were published in the British Journal of Cancer.

“New approaches for relapsed ovarian cancer are desperately needed as there are currently limited effective combinations to treat our patients. The results of this study demonstrated a drug combination that could be an effective treatment for this type of ovarian cancer,” said Alessandro Santin, MDprofessor of obstetrics, gynecology, and reproductive sciences at the Yale School of Medicine and disease-aligned research team leader for the gynecological cancers program at Yale Cancer Center and Smileow Cancer Hospital and lead author of the study.

Ovarian cancer is the deadliest gynecological malignancy. According to the American Cancer Society, nearly 20,000 women will be diagnosed with ovarian cancer in the United States each year and more than 12,000 women will die from it. IXA is a microtubule stabilizing agent that may be beneficial in patients treated with platinum/paclitaxel. Bevacizumab (BEV) is an antibody that prevents the formation of new blood vessels and has shown clinical activity in ovarian cancer.

In this phase II study, researchers randomly assigned 78 patients to receive IXA+BEV or IXA alone. The primary endpoint was progression-free survival (PFS), overall survival (OS), safety, and response rates served as secondary endpoints. The researchers also investigated whether the presence of the TUBB3 protein in the tumor could predict clinical response to these drugs. Among 76 evaluable patients who received IXA+BEV versus IXA, the response rate was 33% versus 8%, with sustained clinical benefit at 6 months in 37% and 3%. Adding BEV significantly improved both PFS (5.5 months versus 2.2 months) and OS (10 months versus 6 months). Both regimens were well tolerated.

“We expect our findings to have major implications for the field of gynecologic oncology, as they add a new, effective treatment for these extremely challenging tumors for which there are otherwise few options,” said the former. author Dana M. Roque, MD, associate professor in the Division of Gynecologic Oncology at the University of Maryland School of Medicine and member of the Marlene & Stewart Greenebaum Comprehensive Cancer Center.

Other Yale authors of the study include: Gloria Huang, MD, Gulden Menderes, MDand Elena Ratner, MD, Natalia Buza, MDStefania Bellone, PhD, Vaagn Andikyan, MD, Mitchell Clark, MD, Masoud Azodi, MD, Peter E. Schwartz, MD, Pei Hui, MD, PhD, Joan R. Tymon-Rosario, Justin Harold, MD, Dennis Mauricio, Bourak Zeybek, and Gary Altwerger, MD.

Funding for the study was provided by RPharm-US, grants from the National Institutes of Health, National Cancer Institute, Deborah Bunn Alley Ovarian Cancer Research Foundation, Discovery to Cure Foundation, Stand Up to Cancer Foundation (SU2C), the Guido Berlucchi Foundation and the Domenic Cicchetti Foundation.

Comments are closed.